John McAuliffe, PhD
Surgical Oncology · Bronx, NYNPI 1205060068
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,325 of the $14,795 with a category attached, or 76.5%. Boston Scientific accounts for 92.3% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2020 at $7,080 and has fallen 90.2% since, to $695 in 2025. Among surgical oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $448.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$14K
- Medical Device Business Services, Inc.$305
- Acell, Inc.$181
- Medtronic$167
- AbbVie$157
- Medline Industries LP$145
- plus $181 from 3 others
Across 2 payments — averaging $65,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$130K
What the payments were for
- Consulting fees$1,3139%
- Speaking & faculty fees$11,32577%
- Travel & lodging$1831%
- Food & beverage$1,66911%
- Education$3052%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 21 | $13,660 |
| Medical Device Business Services, Inc. | 1 | $305 |
| Acell, Inc. | 1 | $181 |
| Medtronic | 1 | $167 |
| AbbVie(2 entities) | 2 | $157 |
| Medline Industries LP | 4 | $145 |
| Intera Oncology, Inc | 1 | $134 |
| Deciphera Pharmaceuticals Inc. | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SpyGlass Discover$6,525
- SPYGLASS$5,250
- SPYSCOPE$1,313
- Signia$167
- AXIOS$146
- STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS$137
- INTERA$134
- GENERAL PULMONARY$108
How this compares
$14,795 in reported general payments places this provider in the 90th percentile of 173 surgical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 16 | $12 |
| Oxycodone Hcl | 16 | $12 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Bronx
- Ali RazaBronx$9K
- Sheldon FeldmanNew York$97K
- Kepal PatelNew York$94K
- Helen CappuccinoBuffalo$70K
- Jose Alberty OllerStaten Island$63K
- Megan WinnerMineola$51K
- George PlitasNew York$39K
- James ParkNew York$28K
- Anna WeissRochester$27K
- Michael LoweNew York$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.